Japan OKs Bayer PAH drug; Sagent sees profit pop; BioMarin works on pay for performance model;

@FiercePharma: Sanofi names Paris-trained Olivier Brandicourt CEO. He will begin at Sanofi April 2. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI earlier: Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot. FierceVaccines story | Follow @CarlyHFierce

> Bayer Healthcare says Adempas, a drug is developed with Merck & Co. has been approved in Japan for the treatment of two kinds of pulmonary arterial hypertension (PAH). Release

> Sagent Pharmaceuticals ($SGNT) reported a 32% increase in revenues and a 41% rise in profit for 2014. Release

> The Indian Pharmaceutical Association is concerned that an overhaul of the industry by the new government will take away too much authority from state regulators. Report

> Germany will encourage the development of new antibiotics that can fight antibiotic-resistant "superbugs." Story

Medical Device News

@FierceMedDev: Integra LifeSciences lays off 49 in Massachusetts as part of facility consolidation drive. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ $GE response GE recalls 10,000+ MRI systems after FDA deems them potentially deadly, citing poor training. Article | Follow @VarunSaxena2

@EmilyWFierce: Check out our weekly roundup of FierceLifeSciences news here! Newsletter | Follow @EmilyWFierce

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for as much as $2.3B. More

> 23andMe nabs FDA marketing clearance for direct-to-consumer genetic carrier test. Story

> New studies shed light on power morcellator devices in surgical procedures. Article

Biotech News

@FierceBiotech: EuroBiotech Report: Novartis makes Israel a priority, U.K. dreams up Alzheimer's R&D hub, Shire defends tax model. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: I love this Pronutria story. VC insiders, star scientist, homeostasis focus on oral biologics. It's what makes Boston/Cambridge special. Article | Follow @JohnCFierce

@DamianFierce: Cerecor is repurposing an old $LLY antidepressant for addiction. Release | Follow @DamianFierce

> Ariad activists rabble for Berger's job and mount a proxy fight. Story

> Novo Nordisk's game-changing oral diabetes drug clears Phase II. Article

> Biotech bonanza helps Bessemer roll out a $1.6B venture fund. Report

And Finally... BioMarin Pharmaceutical ($BMRN) and Sangamo BioSciences ($SGMO) are among companies working on payment plans for gene therapies that would provide large payouts, over a number of years, but only if they are effective. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.